Coronary disease & ACSSecondary analysis
16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction
- Long-term follow-up of the DANAMI-2 randomised trial
- multicentre
Authors' conclusion
The benefit of pPCI over fibrinolysis was maintained at 16-year follow-up.
Study context
- Population
- STEMI patients at 24 referral hospitals and 5 invasive centres in Denmark
- Participants
- 1,572 patients
- Comparison
- Primary PCI vs fibrinolysis
- Primary endpoint
- Composite of:
- Death
- Rehospitalization for myocardial infarction (MI)
- Follow-up
- 16 years
Primary result
Death or rehospitalization for MI
Hazard ratio
0.86
95% CI 0.76–0.98
By group
pPCI vs Fibrinolysis
HR 0.86 (95% CI 0.76–0.98)
As reported in the abstract
Further findings
| Outcome | pPCI | Fibrinolysis | HR (95% CI) | |
|---|---|---|---|---|
| Death or rehospitalization for MI, patients transported for pPCI (subgroup) · 16 years | Not reported in the abstract | 64.1% | 0.82 (0.71–0.96) | |
| Cardiac mortality · 16 years · absolute reduction 4.4% | 18.3% | 22.7% | 0.78 (0.63–0.98) | |
| 0.512Hazard ratio (log scale) |
| Outcome | average postponement (months) (95% CI) |
|---|---|
| Postponement of a main event | 12.3 (5.0–19.5) |
All-cause mortality · 16 years
- No difference in all-cause mortality
Original publication
16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction. Eur Heart J. Published 2 September 2019. doi:10.1093/eurheartj/ehz595
Summarised from the published abstract; every number is checked against it